Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 6INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Non-Small-Cell Lung 926Neoplasms 609Breast Neoplasms 604Colorectal Neoplasms 457Neoplasm Metastasis 394Ovarian Neoplasms 328Melanoma 312Prostatic Neoplasms 311Lung Neoplasms 294Multiple Myeloma 290Recurrence 278Squamous Cell Carcinoma of Head and Neck 246Stomach Neoplasms 229Pancreatic Neoplasms 228Leukemia, Myeloid, Acute 220Triple Negative Breast Neoplasms 190Endometrial Neoplasms 190Carcinoma, Renal Cell 182Lymphoma, Non-Hodgkin 179Carcinoma, Hepatocellular 177Small Cell Lung Carcinoma 165Leukemia, Lymphocytic, Chronic, B-Cell 156Advanced Solid Tumors 154Lymphoma, Follicular 148Urinary Bladder Neoplasms 139Lymphoma, Large B-Cell, Diffuse 138Lymphoma 137Advanced Solid Tumor 137Uterine Cervical Neoplasms 134Head and Neck Neoplasms 134

Interventions

pembrolizumab 1enfortumab vedotin 1Radiation Dose Hypofractionation 1Mitomycin 1Gemcitabine 1Fluorouracil 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Urinary Bladder Diseases × 1 year × Clear all
NCT07566156 2026-05-11

EV-309

Astellas Pharma Inc

Phase 3 Recruiting
390 enrolled
Genitourinary

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT03081858 2025-06-27

Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer

Lipac Oncology LLC

Phase 1/2 Completed
15 enrolled 16 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡